Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-04-18
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how
well it works in combination with cytarabine and idarubicin in treating patients with acute
myeloid leukemia. Pevonedistat may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and
idarubicin, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Given
pevonedistat, cytarabine, and idarubicin may work better in treating patients with acute
myeloid leukemia.